The Role of Fluorodeoxyglucose, 18F-Dihydroxyphenylalanine, 18F-Choline, and 18F-Fluoride in Bone Imaging with Emphasis on Prostate and Breast

Langsteger, Werner; Heinisch, Martin; Fogelman, Ignac

doi:10.1053/j.semnuclmed.2005.09.002

Cited by 184 publications

(146 citation statements)

References 100 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…However, several more recent studies demonstrated that FDG PET (CT) is more accurate than bone scanning for the detection of both osteolytic and osteoblastic lesions. 17,[24][25][26] In the present study PET/CT detected all true positive lesions which were visible on bone scintigraphy and depicted other bone metastases not visible on bone scintigraphy. Moreover, the false positive rate of PET/CT (4%) was lower than that of bone scintigraphy (38%).…”

Section: Discussionmentioning

confidence: 99%

The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques

Aukema¹,

Rutgers²,

Vogel³

et al. 2010

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. In 20 patients (36%) extensive surgery was prevented and treatment was changed to palliative treatment. The sensitivity, specificity, accuracy, positive and negative predictive values of FDG PET/CT were respectively 97%, 92%, 95%, 94% and 96%. M A N U S C R I P T A C C E P T E D ARTICLE IN PRESSConclusions: PET/CT, in addition to conventional imaging techniques, plays an important role in staging patients with locoregional breast cancer recurrence since its result changed the clinical management in almost half of the patients. PET/CT could potentially replace conventional staging imaging in patients with a locoregional breast cancer recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques

Aukema¹,

Rutgers²,

Vogel³

et al. 2010

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

“…Additionally, FDG-PET has become an efficient modality for whole-body scanning in a reasonably short time. 9,10 However, FDG-PET has an unsatisfactory diagnostic value in PC, because the tumor grows relatively slowly in most cases and shows a lower or even absent FDG uptake compared to other cancers. 11,12 Furthermore, the local assessment of PC is sometimes difficult as FDG is excreted in the urine and accumulates in the bladder and prostatic urethra, which effectively masks any uptake in the prostatic parenchyma.…”

Section: Introductionmentioning

confidence: 99%

Incidental diagnosis of a PSA-negative prostate cancer by 18FDG PET/CT in a patient with hypopharyngeal cancer

Bucerius

Ahmadzadehfar

Hortling

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Diagnosis of prostate cancer (PC) still remains critical as non-invasive screening with prostate specific-antigen (PSA) lacks to indicate malignancy of the prostate in some cases. Recent research has shown that clinically meaningful PC can develop in patients with a PSA value o4 ng/ml, frequently defined as upper limit of normal serum PSA levels. Furthermore, both morphological (computed tomography (CT), magnetic resonance imaging, transrectal ultrasound) and functional imaging with 18 fluorodeoxyglucose positron emission tomography (FDG-PET) are associated with several limitations for primary diagnosis of PC. We report a case of an incidentally diagnosed PSAnegative PC by 18 FDG PET/CT in a patient with a previous diagnosis of a hypopharyngeal cancer.

show abstract

“…Concerning the detection of distant cancer metastases, FCH PET/CT could be helpful, in particular in a subgroup of patient at risk for such a spread : initial Gleason score > 7 or PSA serum level > 10 ng/mL or a doubling time of PSA serum levels < 3 months. In series of 49 such patients, Langsteger et al (2006) reported a 4% rate of downstaging (unconfirmed suspicion of bone metastases) and a 16% rate of upstaging (unexpected bone metastases in 4 cases and multiple lymph node metastases in 2 cases) with an impact on management. However, the detection of microscopic lymph node metastases benefits from sentinel lymph node detection which is more sensitive than conventional lymph node detection even including the obturator basin.…”

Section: Introductionmentioning

confidence: 99%

Current evaluation of the clinical utility of Fluoromethylcholine-(18F) PET/CT in Prostate Cancer

Talbot

Chevalme

2008

Braz. arch. biol. technol.

View full text Add to dashboard Cite

This short review is dedicated to the current status of the assessment of a new PET radiopharmaceutical, fluoromethylcholine-(18F) or FCH, which is taken-up by prostate cancer tissue, in contrary to fluorodeoxyglucose-(18F) or FDG. It seems that FCH could become "the FDG of prostate cancer", with the same type of achievements (detection of distant metastases and of occult recurrences, restaging prior to invasive treatments), and the same drawbacks (false negative results in case of small lesions, in particular lymph nodes metastases, and false positive results in case of infection/inflammation, in particular prostatitis). Current evidence is summarised and discussed for each of the potential settings of FCH PET/CT imaging in prostate cancer. The perspectives for granting a marketing authorisation to a FCH preparation are briefly analysed.

show abstract

The Role of Fluorodeoxyglucose, 18F-Dihydroxyphenylalanine, 18F-Choline, and 18F-Fluoride in Bone Imaging with Emphasis on Prostate and Breast

Cited by 184 publications

References 100 publications

The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques

The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques

Incidental diagnosis of a PSA-negative prostate cancer by 18FDG PET/CT in a patient with hypopharyngeal cancer

Current evaluation of the clinical utility of Fluoromethylcholine-(18F) PET/CT in Prostate Cancer

Contact Info

Product

Resources

About